材料科学
体内分布
药物输送
药品
脾脏
纳米技术
肾
基因传递
体内
靶向给药
癌症研究
遗传增强
药理学
生物
医学
生物化学
内科学
免疫学
生物技术
基因
作者
Duhyeon Kim,Chang‐Hee Whang,Jungwoo Hong,Monica Celine Prayogo,Wonsik Jung,Seojung Lee,Hocheol Shin,Yujin Kim,Jiyoung Yu,MinJoong Kim,Kyunggon Kim,Hee‐Seung Lee,Sangyong Jon
标识
DOI:10.1002/adma.202311283
摘要
Abstract Organ‐selective drug delivery is expected to maximize the efficacy of various therapeutic modalities while minimizing their systemic toxicity. Lipid nanoparticles and polymersomes can direct the organ‐selective delivery of mRNAs or gene editing machineries, but their delivery is limited to mostly liver, spleen, and lung. A platform that enables delivery to these and other target organs is urgently needed. Here, a library of glycocalyx‐mimicking nanoparticles (GlyNPs) comprising five randomly combined sugar moieties is generated, and direct in vivo library screening is used to identify GlyNPs with preferential biodistribution in liver, spleen, lung, kidneys, heart, and brain. Each organ‐targeting GlyNP hit show cellular tropism within the organ. Liver, kidney, and spleen‐targeting GlyNP hits equipped with therapeutics effectively can alleviate the symptoms of acetaminophen‐induced liver injury, cisplatin‐induced kidney injury, and immune thrombocytopenia in mice, respectively. Furthermore, the differential organ targeting of GlyNP hits is influenced not by the protein corona but by the sugar moieties displayed on their surface. It is envisioned that the GlyNP‐based platform may enable the organ‐ and cell‐targeted delivery of therapeutic cargoes.
科研通智能强力驱动
Strongly Powered by AbleSci AI